Does the ADIPOQ rs266729 G allele lower adiponectin and increase insulin resistance or type 2 diabetes risk?

The ADIPOQ gene encodes adiponectin, an essential adipokine that regulates insulin sensitivity and glucose homeostasis. A common promoter variant, rs266729 (–11377 C>G), is closely linked to metabolic dysfunction.

Clinical evidence and metabolic risk

• Circulating adiponectin: General adult G-allele carriers (CG and GG genotypes) exhibit significantly reduced circulating adiponectin levels compared to CC homozygotes, presenting with a standardized mean difference of approximately −0.28.
• Insulin resistance: Carriers of the G allele demonstrate increased insulin resistance, characterized by elevated fasting insulin and higher HOMA-IR scores, particularly in populations with higher adiposity.
• Diabetes risk: The rs266729 G allele is an established risk factor for type 2 diabetes. Genetic models demonstrate increased risk across Caucasian, South Asian, and Middle Eastern populations, with odds ratios ranging from 1.13 to 2.0.

Molecular mechanisms

• Transcription factor binding: The rs266729 G allele alters the ADIPOQ promoter sequence, directly disrupting the binding site for the stimulatory transcription factor Sp1.
• Transcriptional downregulation: Impaired Sp1 binding significantly diminishes ADIPOQ promoter transcriptional activity and gene expression.
• Metabolic consequences: This transcriptional deficit directly accounts for lower circulating adiponectin levels. Reduced adipokine signaling subsequently impairs fatty acid oxidation and glucose uptake, driving systemic insulin resistance.

Bottom line

• The ADIPOQ rs266729 G allele is a functional genetic variant that lowers circulating adiponectin (SMD ≈ −0.28) by disrupting Sp1-mediated promoter transcription, consequently increasing the risk of insulin resistance and type 2 diabetes (OR 1.13–2.0) in an ancestry- and adiposity-dependent manner.